Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma
Authors: Angie S. Morris
Sara C. Sebag
John D. Paschke
Amaraporn Wongrakpanich
Kareem Ebeid
Mark E. Anderson
Isabella M. Grumbach
Aliasger K. Salem
University of Iowa
University of Iowa Carver College of Medicine
Mahidol University
Johns Hopkins University
Iowa City Veterans Affairs Healthcare System
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 5-Jun-2017
Citation: Molecular Pharmaceutics. Vol.14, No.6 (2017), 2166-2175
Abstract: © 2017 American Chemical Society. Asthma is a common lung disease affecting over 300 million people worldwide and is associated with increased reactive oxygen species, eosinophilic airway inflammation, bronchoconstriction, and mucus production. Targeting of novel therapeutic agents to the lungs of patients with asthma may improve efficacy of treatments and minimize side effects. We previously demonstrated that Ca2+/calmodulin-dependent protein kinase (CaMKII) is expressed and activated in the bronchial epithelium of asthmatic patients. CaMKII inhibition in murine models of allergic asthma reduces key disease phenotypes, providing the rationale for targeted CaMKII inhibition as a potential therapeutic approach for asthma. Herein we developed a novel cationic nanoparticle (NP)-based system for delivery of the potent and specific CaMKII inhibitor peptide, CaMKIIN, to airways.1 CaMKIIN-loaded NPs abrogated the severity of allergic asthma in a murine model. These findings provide the basis for development of innovative, site-specific drug delivery therapies, particularly for treatment of pulmonary diseases such as asthma.
ISSN: 15438392
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.